Liver Conditions

Overview and Etiology of Hepatitis

• Definition of Hepatitis:

  • Hepatitis is defined pathologically as widespread inflammation of liver tissue.

• Etiological Categories:

  • Viral Infections (Most Common): Classified into primary hepatitis viruses: Hepatitis A ($\text{HAV}$), Hepatitis B ($\text{HBV}$), Hepatitis C ($\text{HCV}$), Hepatitis D ($\text{HDV}$), and Hepatitis E ($\text{HEV}$).

  • Substance Abuse: Toxic cellular injury secondary to heavy, chronic alcohol consumption.

  • Medications and Toxins: Exposure to hepatotoxic drugs, environmental poisons, chemicals, or dietary supplements.

  • Autoimmune Diseases: Cell-mediated and humoral immune destruction of liver parenchyma.

  • Metabolic Abnormalities: Systemic metabolic disruptions leading to hepatic cellular stress.

  • Genetic Factors: Inherited predispositions that increase vulnerability to hepatic damage.

Viral Hepatitis Classifications, Transmission, and Prevention

• Specific Antigens and Antibodies:

  • Each type of viral hepatitis demonstrates distinct serologic biomarkers, featuring specific viral antigens and corresponding host antibody responses.

• Hepatitis A ($\text{HAV}$):

  • Transmission Route: Fecal-oral route via ingestion of food or water contaminated with feces from an infected person.

  • Preventive Measures:

    • Rigorous personal and hand hygiene practices.

    • Safe food handling and sanitary municipal environmental infrastructure.

    • Active immunization with the $\text{HAV}$ vaccine for all children greater than age $1$ ($> 1\,\text{year}$) and high-risk unvaccinated adults.

  • Post-Exposure Prophylaxis ($\text{PEP}$): Administration of intramuscular immune globulin ($\text{IG}$).

  • Treatment Approach: No specific antiviral medication available; relies entirely on supportive clinical care.

• Hepatitis B ($\text{HBV}$):

  • Transmission Route: Percutaneous, permucosal, or sexual exposure to blood, semen, vaginal secretions, or other infective bodily fluids.

  • Preventive Measures: Standard precautions, meticulous hygiene, rigorous donor blood screening, and routine administration of the Hepatitis B recombinant vaccine (infants and high-risk unvaccinated adults).

  • Post-Exposure Prophylaxis ($\text{PEP}$): Combined administration of the Hepatitis B vaccine series and Hepatitis B immune globulin ($\text{HBIG}$).

  • Treatment Approach: Alpha interferon and pegylated interferon (peginterferon); supportive suppression of viral replication.

• Hepatitis C ($\text{HCV}$):

  • Transmission Route: Direct blood-to-blood contact (e.g., contaminated needles, illicit injection drug equipment, or sharp personal items).

  • Preventive Measures: Strict infection control; avoidance of sharing needles, syringes, toothbrushes, razors, or nail scissors.

  • Immunization and Prophylaxis Status: There is no vaccine available for $\text{HCV}$, and no post-exposure prophylaxis exists. Post-exposure management mandates baseline testing followed by serial follow-up testing.

  • Screening Recommendations: Routine universal screening for all individuals born between $1945$ and $1965$.

  • Treatment Approach: Highly effective oral direct-acting antiviral ($\text{DAA}$) medications yielding a sustained cure rate exceeding $98\%$ ($> 98\%$), with historical use of pegylated interferon.

• Hepatitis D ($\text{HDV}$):

  • Transmission Route: Percutaneous or mucosal contact with infected blood.

  • Infection Requirement: Incomplete virus that replicates exclusively in the presence of an active Hepatitis B co-infection or super-infection.

  • Preventive Measures: Immunization against Hepatitis B directly prevents $\text{HDV}$ infection; strict avoidance of sharing contaminated injection equipment, toothbrushes, or razors.

  • Treatment Approach: Interferon therapy.

• Hepatitis E ($\text{HEV}$):

  • Transmission Route: Fecal-oral transmission through drinking water or food supplies contaminated with fecal matter.

  • Preventive Measures: Strict personal hand hygiene and total avoidance of drinking water from potentially unpurified or unsafe sources.

  • Treatment Approach: No specific antiviral therapy available; care is strictly supportive.

Pathophysiology and Risk Factors of Hepatitis

• Mechanisms of Hepatocyte Destruction:

  • Direct Viral Cytopathic Action: Direct cytotoxicity and lysis of hepatocytes mediated by the viral pathogen (notably seen in $\text{HCV}$ infection).

  • Cell-Mediated Immune Destruction: Host immune-mediated response targeting infected hepatocytes displaying viral antigens on their surface (prominent in $\text{HBV}$ and $\text{HCV}$ infections).

• Acute Infection Dynamics:

  • Massive destruction of functional hepatocytes occurs over a short timeframe.

  • Upon resolution of the acute inflammatory cascade, surviving liver cells regenerate in an anatomically and functionally normal architecture.

• Chronic Infection Dynamics:

  • Presents insidiously and remains clinically silent for long periods.

  • Characterized by ongoing, persistent destruction of hepatocytes.

  • Continual cellular necrosis stimulates fibrous tissue proliferation, leading to extensive architectural distortion, permanent fibrosis, and eventual cirrhosis.

• Identified Risk Factors:

  • Engaging in unprotected sexual encounters.

  • Sharing contaminated needles or drug paraphernalia.

  • Consuming water or foodstuffs contaminated with fecal pathogens ($\text{HAV}$, $\text{HEV}$).

  • Direct percutaneous or mucosal exposure to contaminated blood and bodily secretions ($\text{HBV}$, $\text{HCV}$, $\text{HDV}$).

  • Heavy alcohol consumption causing direct toxic injury.

  • Exposure to exogenous industrial chemicals, toxins, hepatotoxic medications, or unregulated nutritional supplements.

  • Host genetic vulnerability.

Clinical Manifestations of Hepatitis: Acute, Convalescent, and Chronic

• Acute Phase Manifestations:

  • Duration and Infectivity: Period of maximal viral infectivity, typically lasting from $1$ to $6\,\text{months}$.

  • Constitutional and Gastrointestinal Symptoms: Anorexia, profound lethargy, progressive weight loss, severe fatigue, nausea, vomiting, right upper quadrant ($\text{RUQ}$) abdominal discomfort and tenderness.

  • Sensory and Systemic Signs: Distaste for cigarettes, reduced or altered sense of smell (hyposmia/dysosmia), low-grade pyrexia, transient erythematous skin rashes, diffuse myalgias, and arthralgias.

  • Icteric vs. Anicteric Presentation:

    • Anicteric hepatitis presents without noticeable bile pigment discoloration.

    • Icteric hepatitis manifests with overt jaundice, tea-colored or dark brown urine (from hyperbilirubinemia excreted through kidneys), light clay-colored stools (secondary to intrahepatic biliary obstruction preventing bilirubin conversion to stercobilin), and intense cutaneous pruritus.

• Convalescent Phase Manifestations:

  • Onset and Duration: Commences immediately as clinical jaundice resolves; persists for weeks to months (typically spanning $2$ to $4\,\text{months}$).

  • Primary Clinical Complaints: Lingering generalized malaise and easy physical fatigability.

  • Physical Findings: Hepatomegaly persists well into the convalescent phase, whereas splenomegaly regresses and subsides.

• Chronic Phase Manifestations:

  • Serum Enzymes: Chronic elevation of serum alanine aminotransferase ($\text{ALT}$) and aspartate aminotransferase ($\text{AST}$), although values can fluctuate or periodically appear within reference ranges.

  • Fluid Accumulation: Ascites and pitting lower extremity edema.

  • Coagulopathy: Thrombocytopenia, purpura, petechiae, easy ecchymosis, and prolonged clotting parameters ($\text{PT/INR}$).

  • Neuromuscular Changes: Asterixis (coarse, bilateral "liver flap" motor tremor seen upon wrist extension).

  • Neurocognitive Decline: Hepatic encephalopathy manifesting as confusion, impaired executive concentration, personality alterations, and severe agitation.

  • Organ Alterations: Palpable hepatomegaly progressing eventually to a firm, shrunken, nodular organ.

  • Dermatologic Manifestations:

    • Palmar erythema: Distinct blanching redness across the thenar and hypothenar eminences.

    • Spider angiomas (spider nevi): Small, dilated, spider-like superficial capillaries occurring on the face, neck, upper trunk, arms, and fingers.

Diagnostic Evaluation for Liver Dysfunction

• Laboratory Blood Analyses:

  • Enzyme Biomarkers: Markedly elevated alanine aminotransferase ($\text{ALT}$), aspartate aminotransferase ($\text{AST}$), and alkaline phosphatase ($\text{ALP}$).

  • Protein Profiles: Decreased serum total protein and circulating serum albumin concentrations.

  • Bilirubin Markers: Elevated conjugated and unconjugated serum bilirubin, elevated urine bilirubin, and altered urinary urobilinogen excretion.

  • Hemostatic Assays: Prolongation of prothrombin time ($\text{PT}$), international normalized ratio ($\text{INR}$), and partial thromboplastin time ($\text{PTT}$).

  • Lipid Profiles: Fluctuations in serum cholesterol concentrations.

  • Viral Serology: Targeted hepatitis antibody and antigen panels evaluating viral proteins and corresponding host immunoglobulin subclasses ($\text{IgM}$ vs. $\text{IgG}$).

• Noninvasive Diagnostic Imaging:

  • Abdominal Ultrasound: Evaluates morphological dimensions, architectural consistency, biliary architecture, and portal vascular patency.

  • Ultrasound Elastography (FibroScan): Noninvasive acoustic imaging technology evaluating hepatic stiffness and the precise stage of parenchyma fibrosis.

• Percutaneous Liver Biopsy (Gold Standard Diagnostic):

  • Extracts a core cylinder of hepatic tissue for microscopic, histopathological examination; definitive for assessing necrosis, architecture, and fibrosis staging.

  • Pre-Procedure Nursing Mandates: Complete patient fasting beginning at midnight prior to the biopsy to ensure safety in the event that emergent surgical exploration is required due to severe bleeding.

  • Post-Procedure Positioning and Monitoring: Position the patient in a strict right side-lying position for several hours to compress the puncture site against the chest wall, splinting the wound. Instruct the patient explicitly to avoid coughing, deep straining, or Valsalva maneuvers.

Interprofessional Care and Pharmacologic Therapies for Hepatitis

• Conservative and Lifestyle Interventions:

  • Nutritional Regimen: Well-balanced dietary intake accompanied by targeted therapeutic vitamin supplementation (particularly B-complex vitamins).

  • Metabolic Rest: Prescribed physical rest with degrees of immobilization tailored to patient symptom severity to reduce metabolic demands on the liver.

  • Chemical Abstinence: Absolute cessation of alcohol ingestion and total avoidance of hepatotoxic pharmaceutical agents, over-the-counter medications, or drugs cleared by hepatic metabolism.

• Antiviral and Supportive Drug Therapeutics:

  • Acute Hepatitis A ($\text{HAV}$): Zero specific antiviral therapies indicated; managed completely through nutritional and fluid support.

  • Acute Hepatitis B ($\text{HBV}$): Pharmacotherapy is reserved exclusively for severe clinical forms to suppress ongoing viral replication.

  • Chronic Hepatitis B ($\text{HBV}$): Subcutaneous alpha interferon and pegylated interferon (peginterferon).

  • Hepatitis C ($\text{HCV}$): Direct-acting antivirals ($\text{DAAs}$) providing rapid clinical cure rates above $98\%$ ($> 98\%$); adjunct usage of pegylated interferon.

  • Symptomatic Supportive Medications:

    • Antiemetics: Indicated to manage debilitating nausea and promote caloric intake.

    • Antihistamines: Administered to mitigate persistent, distressing pruritus.

Occupational Safety and Transmission Precautions for Healthcare Personnel

• Priority 1: Adhere to Comprehensive Infection Control Precautions:

  • Standard precautions must be implemented uniformly across all patient interactions.

• Priority 2: Eliminate Direct Contact with Bodily Fluids:

  • Strictly limit and protect against direct mucosal or skin contact with fresh blood, blood-contaminated exudates, and systemic secretions.

• Priority 3: Universal Presumption of Blood Infectivity:

  • Treat blood specimens and tissue fluids from all medical patients as potentially carrying infectious pathogens.

• Priority 4: Proper Disposal of Sharps:

  • Immediate deposition of all contaminated needles and sharp medical equipment into puncture-resistant, labeled biohazard sharps containers without recapping.

• Priority 5: Implementation of Engineered Needleless Devices:

  • Mandatory utilization of needleless intravenous ($\text{IV}$) access ports, blunt cannulas, and safety-shielded injection equipment whenever available.

Cirrhosis: Pathophysiology and Etiological Subtypes

• Pathophysiology and Definition:

  • Cirrhosis represents the irreversible end-stage of chronic liver disease.

  • Characterized by widespread degeneration and necrosis of parenchymal hepatocytes.

  • Destruction results in the diffuse replacement of normal hepatic lobular architecture by non-functional bands of fibrous scar tissue and irregular, disorganized regenerative nodules.

  • Typically develops gradually over decades of persistent inflammatory exposure.

• Common Etiological Classifications:

  • Primary Causes in the United States: Chronic Hepatitis C virus ($\text{HCV}$) infection, nonalcoholic steatohepatitis ($\text{NASH}$), and alcohol-induced liver disease.

  • Nutritional and Environmental Causes: Chronic malnutrition, extreme weight loss dieting, gastrointestinal malabsorption syndromes, severe obesity, and environmental chemical exposures.

  • Biliary Cirrhosis Subtypes:

    • Primary Biliary Cirrhosis ($\text{PBC}$): Chronic inflammatory destruction localized primarily to intrahepatic bile ducts.

    • Primary Sclerosing Cholangitis ($\text{PSC}$): Autoimmune disease characterized by chronic inflammation, concentric fibrotic obliteration, and strictures of intrahepatic and extrahepatic biliary ducts.

  • Cardiac Cirrhosis: Secondary to long-standing, severe right-sided heart failure. Chronic backpressure causes intense hepatic venous congestion, sinusoidal pooling, parenchymal necrosis, and progressive reticular fibrosis.

Clinical Manifestations of Cirrhosis: Compensated vs. Decompensated

• Compensated Cirrhosis (Early-Stage):

  • Clinical signs may be minimal or absent altogether.

  • Patients often experience insidious fatigue and mild right-upper quadrant hepatomegaly.

  • Baseline liver function tests and serum albumin levels can remain within normal reference limits.

• Decompensated Cirrhosis (Late-Stage Liver Failure):

  • Clinical degradation driven by hepatocyte insufficiency and severe portal hypertension.

  • Constitutional Changes: Progressive cachexia, loss of muscle mass, marked involuntary weight loss, and lingering fetor hepaticus (a distinctive musty, sweet breath odor caused by volatile metabolic byproducts).

  • Dermatologic and Ocular Signs: Deep cutaneous and scleral jaundice, unremitting generalized pruritus without an identifiable rash, prominent palmar erythema, and spider angiomas.

  • Gastrointestinal Alterations: Clay-colored or pale stools, dark amber or tea-colored urine, and impaired fat digestion leading to dyspepsia, bloating, and steatorrhea.

  • Hematologic and Endocrine Disruptions: Thrombocytopenia, spontaneous ecchymosis, splenomegaly, and endocrine imbalances from failed hepatic hormone metabolism (e.g., hyperestrogenism, gynecomastia, testicular atrophy, loss of body hair).

  • Structural Liver Change: The liver ultimately becomes noticeably shrunken, hard, and nodular.

Major Complications of Cirrhosis and Advanced Liver Failure

• Portal Hypertension and Collateral Channels:

  • Fibrotic architectural scarring compresses intrahepatic sinusoids, raising vascular resistance and causing persistently elevated venous pressures throughout the portal venous circulation.

  • Produces congestive splenomegaly, fluid transudation into the peritoneum, and the formation of dilated systemic collateral veins.

  • Collaterals develop where portal and systemic circulations communicate: the lower esophagus, anterior abdominal wall, parietal peritoneum, and rectum.

  • Manifests as caput medusae (a visible sunburst ring of distended periumbilical varices), internal hemorrhoids, and esophageal and gastric varices.

• Esophageal and Gastric Varices:

  • Fragile, distended tortuous veins that develop in the submucosa of the distal esophagus and gastric fundus.

  • Extremely vulnerable to ulceration, mechanical trauma, and sudden rupture.

  • Represents the single most acute, life-threatening complication of decompensated cirrhosis.

• Peripheral Edema:

  • Driven by impaired hepatic synthesis of serum albumin, resulting in decreased intravascular colloidal oncotic pressure.

  • Compounded by increased portacaval venous backpressure.

  • Presents as bilateral dependent lower extremity edema and presacral edema; may precede, coincide with, or follow ascites.

• Ascites:

  • The accumulation of serous peritoneal fluid within the abdominal cavity.

  • Underlying Pathophysiology: Simultaneous portal hypertension, severe hypoalbuminemia (reduced oncotic pull), and secondary hyperaldosteronism (impaired hepatic inactivation of aldosterone causing renal sodium and water retention).

  • Respiratory Compromise: Massive ascites can force the diaphragm upward, generating basilar atelectasis and leading to pleural effusion.

• Hepatic Encephalopathy ($\text{HE}$):

  • Syndrome of neurocognitive decline resulting from the liver's inability to detoxify digestive ammonia into urea, allowing circulating neurotoxins to cross the blood-brain barrier.

  • Neuropsychiatric Findings: Early sleep disturbances, memory impairment, confusion, lethargy, volatile behavioral changes, progressing to profound stupor and coma.

  • Motor Alterations: Asterixis (involuntary wrist-flapping tremors) and apraxia (motor constructional impairment, evident as an inability to write or draw simple shapes, or move a pen from left to right).

• Hepatorenal Syndrome ($\text{HRS}$):

  • Functional renal failure characterized by azotemia, profound oliguria, and intractable ascites, devoid of intrinsic renal architectural or structural pathology.

  • Severe portal hypertension causes intense splanchnic arterial vasodilation, resulting in systemic underfilling that triggers extreme compensatory renal arterial vasoconstriction.

  • Refractory to fluid resuscitation; definitive resolution requires orthotopic liver transplantation.

• Acute Liver Failure Complications:

  • Rapid loss of hepatic cellular function.

  • Major causes of death include severe cerebral edema, cerebellar herniation, and subsequent brainstem compression.

  • High vulnerability to sepsis, severe metabolic acid-base disruptions, acute tubular necrosis, and fatal coagulopathies.

Interprofessional Management of Cirrhosis Complications

• Ascites Management:

  • Dietary Sodium: Strict restriction of dietary sodium intake.

  • Pharmacotherapy: Diuretic administration (combining potassium-sparing agents such as spironolactone with loop diuretics such as furosemide); periodic infusions of concentrated human serum albumin.

  • Therapeutic Paracentesis: Bedside needle aspiration of large volumes of peritoneal fluid to relieve respiratory and abdominal distress.

  • Interventional Shunting: Transjugular intrahepatic portosystemic shunt ($\text{TIPS}$) to decompress the portal system; peritoneovenous shunting is rarely used due to excessive complication rates.

• Esophageal and Gastric Varices Protocol:

  • Primary Bleeding Prophylaxis:

    • Complete avoidance of alcohol, aspirin, and nonsteroidal anti-inflammatory drugs ($\text{NSAIDs}$).

    • Screening upper endoscopy (esophagogastroduodenoscopy) to detect high-risk varices.

    • Daily administration of nonselective $\beta$-adrenergic blockers (e.g., propranolol, nadolol) to decrease high portal venous inflow.

  • Active Hemorrhage Stabilization:

    • Airway protection, emergent hemodynamic resuscitation, rapid intravenous fluid replacement.

    • Transfusion therapy using Packed Red Blood Cells ($\text{PRBCs}$), Fresh Frozen Plasma ($\text{FFP}$), and therapeutic Vitamin K.

    • Intravenous infusions of proton pump inhibitors ($\text{PPIs}$) and systemic prophylactic antibiotics.

    • Vasoactive splanchnic vasoconstrictor drug infusions: Octreotide or vasopressin.

  • Endoscopic Hemostasis: Immediate endoscopic band ligation or sclerotherapy.

  • Balloon Tamponade: Temporary mechanical compression of bleeding vessels via specialized multi-lumen tubes (Sengstaken-Blakemore tube or Minnesota tube).

  • Secondary Prophylaxis and Refractory Interventions: Long-term nonselective $\beta$-blockers, repeated serial band ligations, or portal decompression via $\text{TIPS}$ or surgical shunts (portacaval or distal splenorenal shunts).

• Hepatic Encephalopathy Protocol:

  • Ammonia-Lowering Agents: Oral, nasogastric, or retention enema administration of lactulose, which acidifies the colonic lumen to trap ammonia ($\text{NH}_3$) as non-absorbable ammonium ($\text{NH}_4^+$) and produces an osmotic laxative effect.

  • Nonabsorbable Antibiotics: Oral rifaximin to eradicate ammonia-producing intestinal coliform bacteria.

  • Precipitating Factors: Aggressively prevent constipation, remove pooled old blood from the upper gastrointestinal tract, control active bleeding, and adjust dietary protein intake appropriately.

• Nutritional Support Guidelines:

  • High-caloric targets around $3000\,\text{cal/day}$.

  • High complex carbohydrate composition to minimize endogenous protein breakdown.

  • Moderate to low fat consumption to prevent steatorrhea.

  • Targeted protein supplementation during confirmed protein-calorie malnutrition.

  • Low-sodium constraints tailored for fluid retention.

  • Collaborative engagement with a registered dietitian to incorporate salt-free flavor seasonings.

Nursing Process and Clinical Judgment for Liver Impairment

• Recognize Cues (Comprehensive Assessment):

  • Subjective Data: Elicit detailed information regarding abdominal pain, profound fatigue, fever, anorexia, weight trends, arthralgias, alcohol consumption patterns, recreational injection drug use, vaccination status, and prescription drug allergies.

  • Elimination Inquiries: Detailed assessment of the timing, frequency, color, and consistency of the patient's most recent bowel movement.

  • Objective Physical Inspection:

    • Examine skin and sclera under natural lighting for jaundice, purpura, and ecchymosis.

    • Inspect thenar and hypothenar eminences for bilateral palmar erythema.

    • Inspect facial, neck, upper thoracic, and upper extremity surfaces for spider angiomas.

    • Position patient supine to assess abdominal distension, dullness to percussion, fluid wave, and caput medusae.

• Analyze Cues and Prioritize Nursing Diagnoses:

  • Nutritional Imbalance (Compromised): Related to anorexia, nausea, and vomiting secondary to impaired intestinal absorption and storage of nutrients; evidenced by aversion to food and documented suboptimal caloric intake.

  • Impaired Tissue Integrity: Related to peripheral edema, ascites, and bile-salt-induced pruritus; evidenced by cutaneous excoriations from scratching, taut shiny skin over edematous tissue, and high risk for breakdown.

  • Fluid Volume Imbalance: Related to portal hypertension, hypoalbuminemia, and secondary hyperaldosteronism; evidenced by sudden weight gain, pitting edema, and marked ascites.

  • Activity Intolerance: Related to generalized fatigue, muscle loss, and metabolic dysfunction; evidenced by altered vitals and intolerance during exertion.

  • Risk for Bleeding: Related to altered clotting factor synthesis, thrombocytopenia from hypersplenism, and fragile esophageal or gastric varicosities.

• Generate Solutions (Planning and Goals):

  • Formulate a multidisciplinary plan integrating nursing, medical, and nutritional teams.

  • Implement standardized seizure precautions and fall prevention safety measures (mandatory bed alarms).

  • Conduct regularly scheduled baseline neurological assessments.

  • Core Patient Goals: Achieve subjective relief from pain and itching, avoid acute bleeding or neurological decline, maintain nutritional benchmarks, and regain functional independence.

• Take Actions (Acute and Ambulatory Nursing Implementation):

  • Rest and Activity Balancing: Schedule frequent rest intervals between therapies to minimize liver metabolic demands.

  • Nutritional Facilitation: Provide frequent oral hygiene before meals, serve small, high-density snacks, accommodate personal preferences, and explain dietary sodium and protein modifications.

  • Pruritus Mitigation Strategies:

    • Administer prescribed cholestyramine or hydroxyzine.

    • Provide soothing alkaline baths using sodium bicarbonate or Alpha Keri oil.

    • Apply moisturizing emollients, provide soft non-restrictive bed linens, maintain cool room temperatures, clip fingernails short, and instruct the patient to rub pruritic areas with soft knuckles rather than scratching.

  • Strict Monitoring Protocols: Measure abdominal girth at the umbilicus, record serial extremity circumferences, perform accurate daily weights at the same time, record exact intake and output ($\text{I/O}$), and observe stool and urine color changes.

  • Respiratory Care: Elevate the head of bed to semi-Fowler's or high Fowler's position to ease diaphragmatic compression from ascites; encourage coughing and deep breathing.

  • Edema Care and Tissue Preservation: Utilize pressure-relieving air mattresses, turn the patient at least every $2\,\text{hours}$ ($\text{every } 2\,\text{hours}$), implement passive and active range-of-motion ($\text{ROM}$) exercises, and provide mechanical elevation for severely edematous lower extremities or scrotum.

  • Paracentesis Peri-Procedure Workflow:

    • Direct the patient to completely void the bladder immediately prior to trocar puncture to avoid accidental bladder perforation.

    • Position the patient in a high Fowler's posture or sitting securely over the edge of the bed.

    • Continuously monitor blood pressure, pulse rate, and oxygenation to detect hypovolemic shock caused by acute peritoneal fluid shifts.

    • Inspect puncture dressings closely post-procedure for persistent fluid extravasation, bleeding, or hematoma formation.

  • Acute Liver Failure Specific Nursing Actions:

    • Conduct frequent, serial Glasgow Coma Scale ($\text{GCS}$) and neurological evaluations.

    • Maintain head of bed elevated to 30^\fe\,\text{degrees} ($30^\circ$) to optimize cerebral venous outflow and mitigate elevated intracranial pressure ($\text{ICP}$).

    • Minimize physical stimulation, avoid sudden neck flexion, restrict endotracheal suctioning, and minimize patient straining or agitation.

    • Avoid unnecessary sedating pharmaceuticals.

    • Monitor serum electrolytes, arterial blood gases, blood glucose, and renal indices to detect acute tubular necrosis or hepatorenal syndrome.

  • Ambulatory Transition Care: Provide comprehensive written and verbal instructions detailing disease progression, red-flag symptoms warranting emergency care, community resources, substance-dependence rehabilitation programs, and referrals for home health nursing.

• Evaluate Outcomes:

  • Caloric and fluid consumption consistently meets baseline requirements without gastrointestinal distress.

  • Skin integrity is preserved without ulcerations or excoriations, accompanied by reduction of pruritus and peripheral edema.

  • Fluid, electrolyte, and renal laboratory parameters remain stable.

  • Patient openly acknowledges substance dependency and actively participates in dedicated recovery resources.